세계의 프로바트립탄 숙신산염 정제 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Frovatriptan Succinate Tablets was estimated to be worth US$ 31.15 million in 2024 and is forecast to a readjusted size of US$ 39.55 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Frovatriptan Succinate Tablets cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Frovatriptan Succinate Tablets are selective 5-HT1B/1D receptor agonists, primarily indicated for the treatment of acute migraine attacks. The upstream supply chain involves the synthesis of high-purity active pharmaceutical ingredients (APIs) and chemical intermediates, largely supplied by specialized API manufacturers in Europe and India. Pharmaceutical excipients such as lactose, starch, and microcrystalline cellulose are provided by leading global excipient suppliers.

Downstream customers mainly include neurology departments, headache specialty clinics, retail pharmacies, and online prescription platforms. With the growing population of migraine patients and the increasing demand for effective treatment, Frovatriptan Succinate Tablets are experiencing steady demand growth in both Western and Asian markets. Looking ahead, the rise of personalized medicine and telemedicine prescription services is expected to expand the applications of this drug in the global healthcare landscape.

In 2024, the global average price of Frovatriptan Succinate Tablets is approximately USD 3.74 per tablet, with total sales reaching around 8.33 million tablets.

At present, the global market for Frovatriptan Succinate Tablets demonstrates a dual structure of originator and generic products, positioning it as a mature niche within the triptan class of migraine therapeutics. In developed markets such as the U.S. and Europe, demand remains steady due to clinical guideline endorsements and broad reimbursement coverage. Meanwhile, in Asia-Pacific, particularly China and India, market penetration is accelerating, supported by the entry of local generic manufacturers that enhance affordability and accessibility. Overall, competition is largely driven by pricing strategies and distribution expansion.

From a manufacturing perspective, the production of Frovatriptan Succinate Tablets involves high-precision formulation processes. Common excipients include lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, sodium starch glycolate, magnesium stearate, and specialized film-coating premixes. These excipients are critical for ensuring stability, bioavailability, and patient adherence, underscoring the importance of strict quality control and adherence to CGMP standards. Companies such as Endo Pharmaceuticals, Menarini, Ingenus Pharmaceutical, and Glenmark operate advanced facilities and robust quality management systems to ensure consistent supply and regulatory compliance. The raw material supply chain is divided into APIs and excipients, each subject to rigorous pharmacopoeia testing, highlighting the complexities inherent in scaling up production and enabling global distribution.

Looking ahead, the market is expected to remain relatively stable with modest growth. On one hand, the rising prevalence of migraine and improved diagnosis and treatment rates in emerging markets will sustain demand. On the other hand, the adoption of novel therapies such as CGRP monoclonal antibodies and oral CGRP antagonists is exerting substitution pressure on traditional triptans. While Frovatriptan and related agents may gradually lose share in mature markets, they are expected to retain a strong position in cost-sensitive regions with limited healthcare coverage. Key growth drivers include continued inclusion of triptans in clinical guidelines, the increasing global burden of migraine, and the cost advantage of generics. However, the market faces challenges such as competitive threats from new therapeutic classes, stringent regulatory frameworks on pricing and prescription, and patient adherence issues linked to side effects and the need for combination therapies. Together, these dynamics define the opportunities and competitive landscape of the future market.

This report aims to provide a comprehensive presentation of the global market for Frovatriptan Succinate Tablets, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Frovatriptan Succinate Tablets by region & country, by Type, and by Application.

The Frovatriptan Succinate Tablets market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Frovatriptan Succinate Tablets.

Market Segmentation

By Company

• Endo International
• Menarini
• Ingenus Pharmaceutical
• Glenmark Pharmaceuticals
• SK Chemicals
• Teva
• G.L. Pharma
• Clydesdale Pharma
• Amneal Pharmaceuticals
• Renata PLC
• Qingdao Guoxin Pharmaceutical

Segment by Type

• Original Drug
• Generic Drug

Segment by Application

• Hospital and Clinic
• Retail Pharmacies
• Other

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Frovatriptan Succinate Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Frovatriptan Succinate Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Frovatriptan Succinate Tablets in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Frovatriptan Succinate Tablets Product Introduction
• 1.2 Global Frovatriptan Succinate Tablets Market Size Forecast
  • 1.2.1 Global Frovatriptan Succinate Tablets Sales Value (2020-2031)
  • 1.2.2 Global Frovatriptan Succinate Tablets Sales Volume (2020-2031)
  • 1.2.3 Global Frovatriptan Succinate Tablets Sales Price (2020-2031)
• 1.3 Frovatriptan Succinate Tablets Market Trends & Drivers
  • 1.3.1 Frovatriptan Succinate Tablets Industry Trends
  • 1.3.2 Frovatriptan Succinate Tablets Market Drivers & Opportunity
  • 1.3.3 Frovatriptan Succinate Tablets Market Challenges
  • 1.3.4 Frovatriptan Succinate Tablets Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Frovatriptan Succinate Tablets Players Revenue Ranking (2024)
• 2.2 Global Frovatriptan Succinate Tablets Revenue by Company (2020-2025)
• 2.3 Global Frovatriptan Succinate Tablets Players Sales Volume Ranking (2024)
• 2.4 Global Frovatriptan Succinate Tablets Sales Volume by Company Players (2020-2025)
• 2.5 Global Frovatriptan Succinate Tablets Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Frovatriptan Succinate Tablets Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Frovatriptan Succinate Tablets Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Frovatriptan Succinate Tablets
• 2.9 Frovatriptan Succinate Tablets Market Competitive Analysis
  • 2.9.1 Frovatriptan Succinate Tablets Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Frovatriptan Succinate Tablets Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Frovatriptan Succinate Tablets as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Original Drug
  • 3.1.2 Generic Drug
• 3.2 Global Frovatriptan Succinate Tablets Sales Value by Type
  • 3.2.1 Global Frovatriptan Succinate Tablets Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Frovatriptan Succinate Tablets Sales Value, by Type (2020-2031)
  • 3.2.3 Global Frovatriptan Succinate Tablets Sales Value, by Type (%) (2020-2031)
• 3.3 Global Frovatriptan Succinate Tablets Sales Volume by Type
  • 3.3.1 Global Frovatriptan Succinate Tablets Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Frovatriptan Succinate Tablets Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Frovatriptan Succinate Tablets Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Frovatriptan Succinate Tablets Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Hospital and Clinic
  • 4.1.2 Retail Pharmacies
  • 4.1.3 Other
• 4.2 Global Frovatriptan Succinate Tablets Sales Value by Application
  • 4.2.1 Global Frovatriptan Succinate Tablets Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Frovatriptan Succinate Tablets Sales Value, by Application (2020-2031)
  • 4.2.3 Global Frovatriptan Succinate Tablets Sales Value, by Application (%) (2020-2031)
• 4.3 Global Frovatriptan Succinate Tablets Sales Volume by Application
  • 4.3.1 Global Frovatriptan Succinate Tablets Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Frovatriptan Succinate Tablets Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Frovatriptan Succinate Tablets Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Frovatriptan Succinate Tablets Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Frovatriptan Succinate Tablets Sales Value by Region
  • 5.1.1 Global Frovatriptan Succinate Tablets Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Frovatriptan Succinate Tablets Sales Value by Region (2020-2025)
  • 5.1.3 Global Frovatriptan Succinate Tablets Sales Value by Region (2026-2031)
  • 5.1.4 Global Frovatriptan Succinate Tablets Sales Value by Region (%), (2020-2031)
• 5.2 Global Frovatriptan Succinate Tablets Sales Volume by Region
  • 5.2.1 Global Frovatriptan Succinate Tablets Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Frovatriptan Succinate Tablets Sales Volume by Region (2020-2025)
  • 5.2.3 Global Frovatriptan Succinate Tablets Sales Volume by Region (2026-2031)
  • 5.2.4 Global Frovatriptan Succinate Tablets Sales Volume by Region (%), (2020-2031)
• 5.3 Global Frovatriptan Succinate Tablets Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 5.4.2 North America Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 5.5.2 Europe Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Frovatriptan Succinate Tablets Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 5.7.2 South America Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Frovatriptan Succinate Tablets Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Frovatriptan Succinate Tablets Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Frovatriptan Succinate Tablets Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 6.3.2 United States Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 6.4.2 Europe Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 6.5.2 China Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 6.6.2 Japan Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 6.7.2 South Korea Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Frovatriptan Succinate Tablets Sales Value, 2020-2031
  • 6.9.2 India Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Endo International
  • 7.1.1 Endo International Company Information
  • 7.1.2 Endo International Introduction and Business Overview
  • 7.1.3 Endo International Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Endo International Frovatriptan Succinate Tablets Product Offerings
  • 7.1.5 Endo International Recent Development
• 7.2 Menarini
  • 7.2.1 Menarini Company Information
  • 7.2.2 Menarini Introduction and Business Overview
  • 7.2.3 Menarini Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Menarini Frovatriptan Succinate Tablets Product Offerings
  • 7.2.5 Menarini Recent Development
• 7.3 Ingenus Pharmaceutical
  • 7.3.1 Ingenus Pharmaceutical Company Information
  • 7.3.2 Ingenus Pharmaceutical Introduction and Business Overview
  • 7.3.3 Ingenus Pharmaceutical Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Ingenus Pharmaceutical Frovatriptan Succinate Tablets Product Offerings
  • 7.3.5 Ingenus Pharmaceutical Recent Development
• 7.4 Glenmark Pharmaceuticals
  • 7.4.1 Glenmark Pharmaceuticals Company Information
  • 7.4.2 Glenmark Pharmaceuticals Introduction and Business Overview
  • 7.4.3 Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Product Offerings
  • 7.4.5 Glenmark Pharmaceuticals Recent Development
• 7.5 SK Chemicals
  • 7.5.1 SK Chemicals Company Information
  • 7.5.2 SK Chemicals Introduction and Business Overview
  • 7.5.3 SK Chemicals Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 SK Chemicals Frovatriptan Succinate Tablets Product Offerings
  • 7.5.5 SK Chemicals Recent Development
• 7.6 Teva
  • 7.6.1 Teva Company Information
  • 7.6.2 Teva Introduction and Business Overview
  • 7.6.3 Teva Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Teva Frovatriptan Succinate Tablets Product Offerings
  • 7.6.5 Teva Recent Development
• 7.7 G.L. Pharma
  • 7.7.1 G.L. Pharma Company Information
  • 7.7.2 G.L. Pharma Introduction and Business Overview
  • 7.7.3 G.L. Pharma Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 G.L. Pharma Frovatriptan Succinate Tablets Product Offerings
  • 7.7.5 G.L. Pharma Recent Development
• 7.8 Clydesdale Pharma
  • 7.8.1 Clydesdale Pharma Company Information
  • 7.8.2 Clydesdale Pharma Introduction and Business Overview
  • 7.8.3 Clydesdale Pharma Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Clydesdale Pharma Frovatriptan Succinate Tablets Product Offerings
  • 7.8.5 Clydesdale Pharma Recent Development
• 7.9 Amneal Pharmaceuticals
  • 7.9.1 Amneal Pharmaceuticals Company Information
  • 7.9.2 Amneal Pharmaceuticals Introduction and Business Overview
  • 7.9.3 Amneal Pharmaceuticals Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Amneal Pharmaceuticals Frovatriptan Succinate Tablets Product Offerings
  • 7.9.5 Amneal Pharmaceuticals Recent Development
• 7.10 Renata PLC
  • 7.10.1 Renata PLC Company Information
  • 7.10.2 Renata PLC Introduction and Business Overview
  • 7.10.3 Renata PLC Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Renata PLC Frovatriptan Succinate Tablets Product Offerings
  • 7.10.5 Renata PLC Recent Development
• 7.11 Qingdao Guoxin Pharmaceutical
  • 7.11.1 Qingdao Guoxin Pharmaceutical Company Information
  • 7.11.2 Qingdao Guoxin Pharmaceutical Introduction and Business Overview
  • 7.11.3 Qingdao Guoxin Pharmaceutical Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Qingdao Guoxin Pharmaceutical Frovatriptan Succinate Tablets Product Offerings
  • 7.11.5 Qingdao Guoxin Pharmaceutical Recent Development

8 Industry Chain Analysis

• 8.1 Frovatriptan Succinate Tablets Industrial Chain
• 8.2 Frovatriptan Succinate Tablets Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Frovatriptan Succinate Tablets Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Frovatriptan Succinate Tablets Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer